BIOTRONIK Blog Explore our latest insightful interviews and articles Image Blog Stories Filter and Search Filter by year - Any -20252024202320222021 Search 51 blog articles Image January 4, 2022 Blog “I did not let it throw me off course” How a CLS Pacemaker Helps Cabaret Artist Wolfgang Koch Live Life to the Fullest Image December 21, 2021 Blog Five Things All Cardiac Device Patients Should Know Read the Most Common Patient Questions We Received in 2021 and Answers From Our Experts Image September 29, 2021 Blog Four Ways to Lower Your Atrial Fibrillation Risk Atrial Fibrillation Is the Most Common Type of Heart Arrhythmia and Affects About 30 Million People Worldwide. Image November 15, 2020 Blog Future of Resorbable Scaffolds Looks Rosier As More Data Comes In, There’s Plenty of Reasons to Be Optimistic About Scaffolds Image October 29, 2020 Blog What Role Can ICMs Play in Stroke Prevention? As ICM Use Becomes More Common, How Can Clinics Manage the Workloads That Come With the Longer-Term Diagnostic Windows ICMs Offer? Image Blog Women at BIOTRONIK Four of Our Most Inspiring Leaders Talk About the Most Important Lessons From Their Careers Pagination Page 1 Page 2 Page 3 Page 4 Page 5 Current page 6 Previous page ‹ Previous Subscribe for our News You must have JavaScript enabled to use this form. Title Select TitleMsMrMXDrProf First name Last name Role Please select your roleHealthcare ProfessionalPatient or RelativeJournalistOther Email Phone Country/Region - Select -AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua & BarbudaArgentinaArmeniaArubaAscension IslandAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia & HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCanary IslandsCape VerdeCaribbean NetherlandsCayman IslandsCentral African RepublicCeuta & MelillaChadChileChinaChristmas IslandClipperton IslandCocos (Keeling) IslandsColombiaComorosCongo - BrazzavilleCongo - KinshasaCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d’IvoireDenmarkDiego GarciaDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard & McDonald IslandsHondurasHong Kong SAR ChinaHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacao SAR ChinaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorth KoreaNorth MacedoniaNorwayOmanOutlying OceaniaPakistanPalauPalestinian TerritoriesPanamaPapua New GuineaParaguayPeruPhilippinesPitcairn IslandsPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaRéunionSamoaSan MarinoSarkSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia & South Sandwich IslandsSouth KoreaSouth SudanSpainSri LankaSt. BarthélemySt. HelenaSt. Kitts & NevisSt. LuciaSt. MartinSt. Pierre & MiquelonSt. Vincent & GrenadinesSudanSurinameSvalbard & Jan MayenSwedenSwitzerlandSyriaSão Tomé & PríncipeTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad & TobagoTristan da CunhaTunisiaTurkmenistanTurks & Caicos IslandsTuvaluTürkiyeU.S. Outlying IslandsU.S. Virgin IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamWallis & FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Topic Please select a topicProductsPatientsHealthcare Professionals I prefer to be contacted by Phone Email Message *Fields are mandatory. Latest Press Releases Show all press releases Image June 4, 2025 BUELACH, Switzerland Press Release First Patient Enrolled in Leave Nothing Behind-Trial Comparing Drug-Coated Balloon-Based Strategy to Drug-Eluting Stents in Chronic Total Occlusion Patients Today BIOTRONIK announces the enrollment of the first patient in the Leave Nothing Behind-Trial. The first implantation was performed by Dr. Mohamed Ayoub at the Heart and Diabetes Center North Rhine-Westphalia, Germany. The trial aims to demonstrate the non-inferiority of drug-coated balloons (DCB) or DCBs in combination with Resorbable Magnesium Scaffolds (RMS) compared to drug-eluting stents (DES) in chronic total occlusions (CTO) in percutaneous coronary interventions (PCI). The prospective, single-center, single-blind, randomized trial evaluates the efficacy of the Pantera ® Lux ® DCB and Image May 21, 2025 PARIS, France Press Release BIOMAG-I Data Shows No New Events between Two and Three Years in Target Lesion Failure with Freesolve Resorbable Magnesium Scaffold New results from the BIOMAG-I first-in-human trial demonstrated an excellent safety and efficacy profile for Freesolve ®, BIOTRONIK’s third-generation resorbable magnesium scaffold (RMS) at three years follow-up. Prof. Dr. Michael Haude presented these new data at the EuroPCR 2025 conference in Paris. At the 36-month follow-up, the target lesion failure (TLF) rate remained at 3.5%, consisting of four cases of clinically driven target lesion revascularization (CD-TLR), of which only one event occurred beyond the resorption period of the scaffold. No cases of target-vessel myocardial infarction Image February 27, 2025 BERLIN, Germany BIOTRONIK Driving the Future of Active Device Business BIOTRONIK Driving the Future of Active Device Business BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next Press Contact Corporate Public Relations & Communications press@biotronik.com +49 (0) 30 68905 1414 Get in contact
Image January 4, 2022 Blog “I did not let it throw me off course” How a CLS Pacemaker Helps Cabaret Artist Wolfgang Koch Live Life to the Fullest
Image January 4, 2022 Blog “I did not let it throw me off course” How a CLS Pacemaker Helps Cabaret Artist Wolfgang Koch Live Life to the Fullest
Image December 21, 2021 Blog Five Things All Cardiac Device Patients Should Know Read the Most Common Patient Questions We Received in 2021 and Answers From Our Experts
Image December 21, 2021 Blog Five Things All Cardiac Device Patients Should Know Read the Most Common Patient Questions We Received in 2021 and Answers From Our Experts
Image September 29, 2021 Blog Four Ways to Lower Your Atrial Fibrillation Risk Atrial Fibrillation Is the Most Common Type of Heart Arrhythmia and Affects About 30 Million People Worldwide.
Image September 29, 2021 Blog Four Ways to Lower Your Atrial Fibrillation Risk Atrial Fibrillation Is the Most Common Type of Heart Arrhythmia and Affects About 30 Million People Worldwide.
Image November 15, 2020 Blog Future of Resorbable Scaffolds Looks Rosier As More Data Comes In, There’s Plenty of Reasons to Be Optimistic About Scaffolds
Image November 15, 2020 Blog Future of Resorbable Scaffolds Looks Rosier As More Data Comes In, There’s Plenty of Reasons to Be Optimistic About Scaffolds
Image October 29, 2020 Blog What Role Can ICMs Play in Stroke Prevention? As ICM Use Becomes More Common, How Can Clinics Manage the Workloads That Come With the Longer-Term Diagnostic Windows ICMs Offer?
Image October 29, 2020 Blog What Role Can ICMs Play in Stroke Prevention? As ICM Use Becomes More Common, How Can Clinics Manage the Workloads That Come With the Longer-Term Diagnostic Windows ICMs Offer?
Image Blog Women at BIOTRONIK Four of Our Most Inspiring Leaders Talk About the Most Important Lessons From Their Careers
Image Blog Women at BIOTRONIK Four of Our Most Inspiring Leaders Talk About the Most Important Lessons From Their Careers
Image June 4, 2025 BUELACH, Switzerland Press Release First Patient Enrolled in Leave Nothing Behind-Trial Comparing Drug-Coated Balloon-Based Strategy to Drug-Eluting Stents in Chronic Total Occlusion Patients Today BIOTRONIK announces the enrollment of the first patient in the Leave Nothing Behind-Trial. The first implantation was performed by Dr. Mohamed Ayoub at the Heart and Diabetes Center North Rhine-Westphalia, Germany. The trial aims to demonstrate the non-inferiority of drug-coated balloons (DCB) or DCBs in combination with Resorbable Magnesium Scaffolds (RMS) compared to drug-eluting stents (DES) in chronic total occlusions (CTO) in percutaneous coronary interventions (PCI). The prospective, single-center, single-blind, randomized trial evaluates the efficacy of the Pantera ® Lux ® DCB and
Image June 4, 2025 BUELACH, Switzerland Press Release First Patient Enrolled in Leave Nothing Behind-Trial Comparing Drug-Coated Balloon-Based Strategy to Drug-Eluting Stents in Chronic Total Occlusion Patients Today BIOTRONIK announces the enrollment of the first patient in the Leave Nothing Behind-Trial. The first implantation was performed by Dr. Mohamed Ayoub at the Heart and Diabetes Center North Rhine-Westphalia, Germany. The trial aims to demonstrate the non-inferiority of drug-coated balloons (DCB) or DCBs in combination with Resorbable Magnesium Scaffolds (RMS) compared to drug-eluting stents (DES) in chronic total occlusions (CTO) in percutaneous coronary interventions (PCI). The prospective, single-center, single-blind, randomized trial evaluates the efficacy of the Pantera ® Lux ® DCB and
Image May 21, 2025 PARIS, France Press Release BIOMAG-I Data Shows No New Events between Two and Three Years in Target Lesion Failure with Freesolve Resorbable Magnesium Scaffold New results from the BIOMAG-I first-in-human trial demonstrated an excellent safety and efficacy profile for Freesolve ®, BIOTRONIK’s third-generation resorbable magnesium scaffold (RMS) at three years follow-up. Prof. Dr. Michael Haude presented these new data at the EuroPCR 2025 conference in Paris. At the 36-month follow-up, the target lesion failure (TLF) rate remained at 3.5%, consisting of four cases of clinically driven target lesion revascularization (CD-TLR), of which only one event occurred beyond the resorption period of the scaffold. No cases of target-vessel myocardial infarction
Image May 21, 2025 PARIS, France Press Release BIOMAG-I Data Shows No New Events between Two and Three Years in Target Lesion Failure with Freesolve Resorbable Magnesium Scaffold New results from the BIOMAG-I first-in-human trial demonstrated an excellent safety and efficacy profile for Freesolve ®, BIOTRONIK’s third-generation resorbable magnesium scaffold (RMS) at three years follow-up. Prof. Dr. Michael Haude presented these new data at the EuroPCR 2025 conference in Paris. At the 36-month follow-up, the target lesion failure (TLF) rate remained at 3.5%, consisting of four cases of clinically driven target lesion revascularization (CD-TLR), of which only one event occurred beyond the resorption period of the scaffold. No cases of target-vessel myocardial infarction
Image February 27, 2025 BERLIN, Germany BIOTRONIK Driving the Future of Active Device Business BIOTRONIK Driving the Future of Active Device Business BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next
Image February 27, 2025 BERLIN, Germany BIOTRONIK Driving the Future of Active Device Business BIOTRONIK Driving the Future of Active Device Business BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next